Objective: In Japan, androgen deprivation therapy is employed as the primary therapy for prostate cancer in more than 50% of patients, which is a percentage larger than that in the USA. The adverse effects of androgen deprivation therapy on body composition and lipid profile associated with metabolic syndrome have been reported mainly in Caucasian populations, and few studies have been performed in East Asian populations, including Japanese.
Methods: This study enrolled 39 Japanese patients who were starting to receive androgen deprivation therapy for prostate cancer. Subjects were evaluated at baseline and at 3, 6, 9 and 12 months. Body composition and lipid profiles were measured by bioelectrical impedance analysis and using blood samples, respectively.
Results: The volume of fat and visceral fat was significantly increased 6 months after the treatment and continued to increase until 12 months. On the other hand, skeletal muscle was significantly decreased during the same period. The serum concentration of total cholesterol and low-density lipoprotein cholesterol increased significantly over the same period.
Conclusions: Androgen deprivation therapy changed the body composition and lipid profile of men with prostate cancer. It was demonstrated that even Japanese patients with prostate cancer who are treated with androgen deprivation therapy have the risk of developing metabolic syndrome.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jjco/hyr005 | DOI Listing |
J Natl Compr Canc Netw
March 2025
5Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA.
Background: Rural areas have higher cardiovascular disease (CVD) incidence and age-adjusted mortality rates in the general population. However, the impact of rurality on CVD development and outcomes in patients with prostate cancer (PC) remains unclear.
Patients And Methods: This retrospective cohort study used the SEER-Medicare database to analyze males aged ≥65 years diagnosed with PC between 2009 and 2017.
JAMA
March 2025
Department of Medicine, University of Washington, Seattle.
Importance: Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299 010 new cases and 35 250 deaths in 2024. Prostate cancer is the second most common cancer in men worldwide, with 1 466 680 new cases and 396 792 deaths in 2022.
Observations: The most common type of prostate cancer is adenocarcinoma (≥99%), and the median age at diagnosis is 67 years.
Cureus
February 2025
Department of Urology, University Hospital Galway, Galway, IRL.
Testicular metastases from prostate cancer (PCa) are exceedingly rare and are typically accompanied by other metastatic sites. We present the case of an 82-year-old male patient who developed isolated testicular metastasis 15 years after undergoing radiotherapy and androgen deprivation therapy (ADT) for localized PCa. The patient presented with a palpable left testicular mass, which was confirmed to be a metastatic prostate adenocarcinoma by histopathological and immunohistochemical analyses.
View Article and Find Full Text PDFJ Clin Nurs
March 2025
Department of Nursing, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Aim: To explore the perceptions of patients with prostate cancer undergoing androgen deprivation therapy towards mobile health interventions.
Design: The study employed a qualitative descriptive design.
Methods: Seventeen participants were recruited from tertiary care hospitals from November 2022 to June 2023.
Bioorg Med Chem
February 2025
Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, USA; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY 11794-3400, USA. Electronic address:
Prostate cancer (PCa) is one of the most common malignancies diagnosed among men and is the second leading cause of cancer-related death. Despite recent advancements in early diagnosis of PCa, androgen deprivation therapy (ADT) remains the most common treatment of PCa. Docetaxel (DTX) and Cabazitaxel (CTX) are two of the most extensively used drugs for metastatic castration-resistant prostate cancer (mCRPC).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!